{"id":"folfiri-cures","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"60-70","effect":"Nausea/vomiting"},{"rate":"30-40","effect":"Anemia"},{"rate":"20-30","effect":"Mucositis"},{"rate":"50-60","effect":"Fatigue"},{"rate":"20-30","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFIRI consists of fluorouracil (5-FU), leucovorin (folinic acid), and irinotecan (CPT-11). Fluorouracil is a pyrimidine antimetabolite that inhibits thymidylate synthase and disrupts DNA synthesis. Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding and causes double-strand breaks. Leucovorin enhances the cytotoxicity of 5-FU by stabilizing its binding to thymidylate synthase.","oneSentence":"FOLFIRI is a chemotherapy regimen that combines three drugs to inhibit DNA synthesis and cell division, primarily used to treat colorectal cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:44:06.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Locally advanced colorectal cancer"}]},"trialDetails":[{"nctId":"NCT03117972","phase":"PHASE2","title":"Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-08-04","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT06197425","phase":"PHASE3","title":"Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2024-01","conditions":"Colon or Upper Rectum Adenocarcinoma","enrollment":1660}],"_emaApprovals":[],"_faersSignals":[{"count":222,"reaction":"DIARRHOEA"},{"count":192,"reaction":"NEUTROPENIA"},{"count":157,"reaction":"DISEASE PROGRESSION"},{"count":152,"reaction":"DRUG INEFFECTIVE"},{"count":127,"reaction":"FATIGUE"},{"count":127,"reaction":"NAUSEA"},{"count":127,"reaction":"OFF LABEL USE"},{"count":116,"reaction":"THROMBOCYTOPENIA"},{"count":110,"reaction":"ANAEMIA"},{"count":106,"reaction":"MALIGNANT NEOPLASM PROGRESSION"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"\"FOLFIRI\" cures","genericName":"\"FOLFIRI\" cures","companyName":"Centre Hospitalier Universitaire Dijon","companyId":"centre-hospitalier-universitaire-dijon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFIRI is a chemotherapy regimen that combines three drugs to inhibit DNA synthesis and cell division, primarily used to treat colorectal cancer. Used for Metastatic colorectal cancer, Locally advanced colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}